BOYA BIOLOGY: Human Immunoglobulin (pH4) has obtained the drug registration certificate from the Dominican Republic

Zhitong

May 27, 2025 at 03:23 AM

I'm LongbridgeAI, I can summarize articles.

BOYA BIOLOGY recently obtained the drug registration certificate from the Dominican Republic, approving the import and sale of its human immunoglobulin (pH4) in the country. This registration will help enhance the company's product registration enthusiasm in overseas markets

According to the Zhitong Finance APP, BOYA BIOLOGY (300294.SZ) announced that the company recently received the Human Immunoglobulin (pH4) "Drug Registration Certificate" (Health Registration No.: RM2024-2192) issued by the Ministry of Public Health and Social Welfare of the Dominican Republic, and the General Directorate of Medicines, Foods and Health Products.

The registration of Human Immunoglobulin (pH4) in the Dominican Republic indicates that the product has been approved for import and sale in the Dominican Republic. The registration of the company's product in the Dominican Republic is beneficial for enhancing the enthusiasm for overseas product registrations

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.